# UroGen Pharma (URGN) — Earnings

URGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/urgn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.28 |
| EPS estimate | −$0.28 |
| EPS surprise | +0.00% |
| Revenue surprise | +11.39% |
| Revenue | $72.5M |
| Revenue estimate | $65.0M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/4eb10d8b-4022-4e9b-bb6a-4d888010f4d3.html) |

UroGen reported Q2 2026 results on August 5, 2026. It posted a loss of $0.28 per share, matching the estimate. Revenue of $72.5 million beat the $65.0 million consensus by 11.39% and was the highest in the table. Compared with Q2 2025, revenue roughly tripled from $24.2 million and the loss narrowed from $1.05 per share.

Every quarter in the table was a loss, but the losses have narrowed. Annual losses were $4.78 per share in 2022, $3.73 in 2023, $3.23 in 2024 and $3.20 in 2025, and Q2 2026's loss was the smallest in the table. Revenue climbed from $64.4 million in 2022 to $109.8 million in 2025 and has risen in each of the last five quarters. The first half of 2026 brought $123.5 million in revenue, more than all of 2025. Against EPS estimates, UroGen beat 9 times in 20 quarters, missed 10 times and matched once.

UroGen reported Q3 between November 6 and November 15 in each of the past five years. That points to early or mid-November 2026 for the next report. It will show whether revenue keeps growing and the loss per share keeps narrowing.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.28 | −$0.28 | 0.00% | $65.0M | $72.5M |
| Q1 2026 | May 6, 2026 | −$0.48 | −$0.47 | 2.57% | $44.8M | $51.0M |
| Q4 2025 | Mar 2, 2026 | −$0.50 | −$0.54 | -7.48% | $39.9M | $37.8M |
| Q3 2025 | Nov 6, 2025 | −$0.69 | −$0.69 | 0.33% | $32.5M | $27.5M |
| Q2 2025 | Aug 7, 2025 | −$0.86 | −$1.05 | -21.43% | $23.3M | $24.2M |
| Q1 2025 | May 12, 2025 | −$0.80 | −$0.92 | -15.10% | $22.8M | $20.3M |
| Q4 2024 | Mar 10, 2025 | −$0.72 | −$0.80 | -11.16% | $25.6M | $24.6M |
| Q3 2024 | Nov 6, 2024 | −$0.82 | −$0.55 | 32.69% | $24.2M | $25.2M |
| Q2 2024 | Aug 13, 2024 | −$0.83 | −$0.91 | -9.38% | $24.0M | $21.8M |
| Q1 2024 | May 13, 2024 | −$0.87 | −$0.97 | -11.93% | $21.4M | $18.8M |
| Q4 2023 | Mar 14, 2024 | −$0.68 | −$0.72 | -5.88% | $22.6M | $23.5M |
| Q3 2023 | Nov 14, 2023 | −$0.85 | −$0.68 | 19.62% | $20.0M | $20.9M |
| Q2 2023 | Aug 10, 2023 | −$1.14 | −$1.03 | 9.33% | $20.1M | $21.1M |
| Q1 2023 | May 11, 2023 | −$1.33 | −$1.30 | 2.26% | $17.1M | $17.2M |
| Q4 2022 | Mar 22, 2023 | −$1.07 | −$1.22 | -13.67% | $18.5M | $18.1M |
| Q3 2022 | Nov 10, 2022 | −$1.16 | −$1.13 | 2.31% | $20.1M | $16.1M |
| Q2 2022 | Aug 11, 2022 | −$1.28 | −$1.18 | 7.45% | $17.2M | $16.6M |
| Q1 2022 | May 10, 2022 | −$1.33 | −$1.25 | 6.25% | $15.2M | $13.6M |
| Q4 2021 | Mar 21, 2022 | −$1.18 | −$1.27 | -8.09% | $16.2M | $16.2M |
| Q3 2021 | Nov 15, 2021 | −$1.28 | −$1.35 | -5.47% | $15.4M | $11.4M |

## Frequently Asked Questions

### When did UroGen Pharma (URGN) last report earnings?

UroGen Pharma last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did URGN beat earnings estimates?

UroGen Pharma reported EPS of −$0.28 for Q2 2026, in line with the −$0.28 consensus estimate.

### How much revenue did URGN report last quarter?

UroGen Pharma reported $72.5M in revenue for Q2 2026, against a consensus estimate of $65.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).